DPP-4 inhibitors may improve the mortality of coronavirus disease 2019: A meta-analysis

A novel coronavirus outbreak of global health concern

(2020) Chen Wang et al.   LANCET

SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor

(2020) Markus Hoffmann et al.   CELL

COVID-19 and diabetes: Can DPP4 inhibition play a role?

(2020) Gianluca Iacobellis   DIABETES RESEARCH AND CLINICAL PRACTICE

SARS-CoV-2 and DPP4 inhibition: Is it time to pray for Janus Bifrons?

(2020) Dario Pitocco et al.   DIABETES RESEARCH AND CLINICAL PRACTICE

Phenotypic characteristics and prognosis of inpatients with COVID-19 and diabetes: the CORONADO study

(2020) Bertrand Cariou et al.   DIABETOLOGIA

Diagnostic Utility of Clinical Laboratory Data Determinations for Patients with the Severe COVID‐19

(2020) Yong Gao et al.   JOURNAL OF MEDICAL VIROLOGY

COVID-19: consider cytokine storm syndromes and immunosuppression

(2020) Puja Mehta et al.   LANCET

Assessment of risk, severity, mortality, glycemic control and antidiabetic agents in patients with diabetes and COVID-19: A narrative review

(2020) Awadhesh Kumar Singh et al.   DIABETES RESEARCH AND CLINICAL PRACTICE

Higher body mass index is an important risk factor in COVID-19 patients: a systematic review and meta-analysis

(2020) Vivek Singh Malik et al.   ENVIRONMENTAL SCIENCE AND POLLUTION RESEARCH

Molecular basis of binding between MERS-CoV and CD26s from seven bat species

(2019) Yuan Yuan et al.   JOURNAL OF VIROLOGY

Dipeptidyl peptidase IV (DPP-4) inhibition alleviates pulmonary arterial remodeling in experimental pulmonary hypertension

(2018) Jian Xu et al.   LABORATORY INVESTIGATION

DPP4 inhibition by sitagliptin attenuates LPS-induced lung injury in mice

(2018) Takeshi Kawasaki et al.   AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY

Hepatocyte-secreted DPP4 in obesity promotes adipose inflammation and insulin resistance

(2018) Devram S. Ghorpade et al.   NATURE

Safety and Efficacy of DPP4 Inhibitor and Basal Insulin in Type 2 Diabetes: An Updated Review and Challenging Clinical Scenarios

(2018) Fernando Gomez-Peralta et al.   Diabetes Therapy

SARS and MERS: recent insights into emerging coronaviruses

(2016) Emmie de Wit et al.   NATURE REVIEWS MICROBIOLOGY

The Dipeptidyl Peptidase Family, Prolyl Oligopeptidase, and Prolyl Carboxypeptidase in the Immune System and Inflammatory Disease, Including Atherosclerosis

(2015) Yannick Waumans et al.   Frontiers in Immunology

Obese patients have higher circulating protein levels of dipeptidyl peptidase IV

(2014) Andreas Stengel et al.   PEPTIDES

Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC

(2013) V. Stalin Raj et al.   NATURE

Glucagon-like peptide-1 inhibits adipose tissue macrophage infiltration and inflammation in an obese mouse model of diabetes

(2012) Y.-S. Lee et al.   DIABETOLOGIA

Plasma dipeptidyl peptidase 4 activity correlates with body mass index and the plasma adiponectin concentration in healthy young people

(2012) Yasushi Kirino et al.   ENDOCRINE JOURNAL

Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses

(2010) Andreas Stang   EUROPEAN JOURNAL OF EPIDEMIOLOGY

Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement

(2009) David Moher et al.   PLOS MEDICINE